OxiGene vascular-disrupting drugs, anti-angiogenic agents may have synergies, oncology researcher says

By Angela McDaniels

Seattle, Nov. 10 - OxiGene Inc. said that oncology researcher Robert Kerbel of the University of Toronto noted there are potential anti-tumor effects that are achievable by combining vascular-disrupting agents, such as OxiGene's Combretastatin A4P and OXi4503, with anti-angiogenic agents.

The comments were made at the American Association for Cancer Research's Anti-Angiogenesis and Drug Delivery to Tumors Conference in Waltham, Mass.

"Considering the potentially synergistic effects of these types of compounds that have been observed in preclinical models, it is reasonable to expect that the combination has the potential to yield massive tumor necrosis and virtually destroy all regions of a solid tumor," said Kerbel, according to an OxiGene news release.

"A vascular-disrupting agent, like CA4P or OXi4503, could be used to cause rapid and massive destruction of the central tumor region, while an anti-angiogenic agent would prevent the onset of neovascularization, or regrowth of blood vessels, that enable a tumor to survive and proliferate after cancer therapy."

OxiGene is a pharmaceutical company based in Waltham, Mass., that develops small-molecule therapeutics to treat cancer and eye diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.